Advertisement

PentaVision

Ophthalmology Management

Article

Spotlight on Technology & Technique: A New Addition to the Excimer Family

Bausch + Lomb's TENEO excimer laser is small and speedy.

Lindsey Getz, contributing writer
Ophthalmology Management April 1, 2025 Vol 29, Issue April 2025 Page(s): 11, 44

Clinical Report: Spotlight on Technology & Technique: A New Addition to the Excimer Family

Overview

The Bausch + Lomb TENEO excimer laser, recently FDA-approved for LASIK, offers significant advancements in speed and precision for treating myopia and myopic astigmatism. Its unique features, including a fast eye-tracker and no need for nomograms, promise improved patient outcomes and operational efficiency.

Background

The introduction of the TENEO excimer laser marks a significant development in LASIK technology, being the first new excimer platform approved in the U.S. in nearly two decades. Enhanced speed and accuracy in laser surgery are critical for improving patient outcomes and satisfaction. As LASIK procedures continue to evolve, understanding the implications of new technologies is essential for optimizing surgical practices.

Data Highlights

Outcome MeasurePre-SurgeryPost-Surgery
Mean Manifest Refraction Spherical Equivalent (D)-5.67 ± 2.52-0.04 ± 0.32
Uncorrected Distance Visual Acuity (20/25 or better)N/A97.8%
Corrected Distance Visual Acuity (20/25 or better)N/A100%

Key Findings

  • The TENEO excimer laser operates at 1,740Hz, making it the fastest on the market.
  • It corrects at 1.2 seconds per diopter, enhancing treatment efficiency.
  • 97.8% of eyes achieved uncorrected distance visual acuity of 20/25 or better at 9 months post-surgery.
  • No nomogram is required, reducing the risk of transcription errors and streamlining surgical planning.
  • The compact design of the laser allows for better space utilization in clinical settings.
  • Improved patient comfort is achieved through ergonomic design features, including a customizable treatment bed.

Clinical Implications

The TENEO excimer laser's rapid operation and intuitive design may lead to quicker recovery times and improved surgical outcomes. Its compact size and reduced need for complex planning can enhance workflow efficiency in ophthalmic practices.

Conclusion

The TENEO excimer laser represents a significant advancement in LASIK technology, with promising outcomes that may enhance both patient satisfaction and operational efficiency in surgical settings.

References

  1. Bausch + Lomb, Bausch + Lomb Corporation, 2024 -- Bausch + Lomb Announces Publication of TENEO™ Excimer Laser Clinical Trial Results in Journal of Refractive Surgery
  2. American Academy of Ophthalmology, PubMed, 2022 -- Refractive Surgery Preferred Practice Pattern®
  3. Ophthalmology Management, Robert Murphy, 2012 -- Upgrades and Advances In Femto and Excimer Lasers
  4. Ophthalmology Management — Upgrades and Advances In Femto and Excimer Lasers
  5. Ophthalmology Management — Spotlight on Technology & Technique
  6. Retinal Physician — FOCUS ON...
  7. Refractive Surgery Preferred Practice Pattern® - PubMed
  8. P990027.S021.SSED.11.22.2023.pdf
  9. Bausch + Lomb Announces Publication of TENEO™ Excimer Laser Clinical Trial Results in Journal of Refractive Surgery | Bausch + Lomb Corporation
  10. One‐Year Outcomes of Topography‐Guided LASIK for Myopia and Astigmatism - PMC